Jubilant Pharmova Ltd reported a strong performance for the first quarter of FY26, with its consolidated net profit rising 48% year-on-year to INR 60 crore, up from INR 41 crore in Q1 FY25. Total revenue for the quarter grew 10% to INR 1,650 crore, compared to INR 1,500 crore in the corresponding period last year.

The growth was primarily driven by improved operational efficiencies and consistent performance across core segments, especially in Contract Development and Manufacturing Organisation (CDMO) services and specialty pharmaceuticals. The radiopharma and allergy therapy divisions also maintained steady demand, contributing to overall profitability.

Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased 22% to INR 278 crore, from INR 227 crore in Q1 FY25. The EBITDA margin improved to 16.8%, compared to 15.1% a year ago, supported by cost optimisation and a favourable product mix.

“Our Q1 FY26 results underscore the strength of our strategy and diversified portfolio,” said Shyam Bhartia, Chairman and Managing Director, Jubilant Pharmova. “Strong momentum in the CDMO space, along with sustained demand in radiopharma and allergy therapies, positions us well for continued profitable growth.”

The Pharmaceuticals segment contributed INR 1,132 crore to the overall revenue, marking an 8% increase year-on-year. The company highlighted continued investments in sterile injectables and specialty product capacity to support future growth.

The Drug Discovery and Development Solutions (DDDS) vertical, operating under Jubilant Biosys, delivered steady performance with revenues of INR 235 crore, driven by consistent client demand and timely project execution.

Going forward, Jubilant Pharmova aims to enhance its R&D and manufacturing capabilities to seize opportunities in the evolving global pharmaceutical landscape. The company remains focused on long-term value creation through innovation, efficiency, and expanding its presence in high-margin therapeutic segments.

Jubilant Pharmova is a global integrated pharmaceutical and life sciences company, engaged in the manufacture of APIs, generics, specialty pharmaceuticals, and providing contract research and development services.